Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance Issues

Member Theresa Carnegie will be speaking on the panel for the Strafford webinar "Executive Orders Targeting Prescription Drug Prices: Agency Objectives, Healthcare Industry Impact, Compliance Issues."

Description:  

The Trump administration recently issued two executive orders aimed at lowering prescriptions drug prices and addressing drug pricing strategies—"Lowering Drug Prices by Once Again Putting Americans First" on Apr. 15, 2025 (April EO) and "Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients" on May 12, 2025 (May EO).  

The April EO was the first significant action taken by the new administration to address drug prices in various areas, including pricing related to pharmacy benefit managers, Medicare and Medicaid, international importation, and competition in drug manufacturing. The May EO directed federal agencies to implement policies to tie prescription drug prices to international price targets and to facilitate direct to consumer sales at the most favored nation price. While each EO contains broad mandates to agencies, many questions as to how these will be accomplished are left unanswered, creating compliance challenges for those in the healthcare industry.  

Therefore, counsel should understand the EOs' objectives, agency impact and action taken to date to fulfill these objectives, and how healthcare clients may be affected in order to help them navigate this rapidly evolving regulatory landscape. 

Listen as our expert panel closely examines the EOs and how they reflect the administration's policy objectives related to prescription drug pricing. The panel will discuss related agency action and address how these may impact the healthcare industry. The panel will also offer best practices for compliance.